A Phase 2/3 interventional study of Cancer ablation and Life information rehabilitation therapy in Advanced Gastric Cancer, sponsored by Fuda Cancer Hospital, Guangzhou. Completed at 1 site in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-25.
Sponsored by Fuda Cancer Hospital, Guangzhou · Phase 2/3, Interventional, and Treatment
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable gastric cancer.
By enrolling patients with unresectable gastric cancer adapted to enrolled criteria,this study will document for the first time the synergistic effect of cancer according to local relief degree,progress free survival(PFS)and overall survival(OS).
Fuda Cancer Hospital, Guangzhou is the lead sponsor of 116 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (\>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Device: Cancer ablation
In this group,the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Drug: Life information rehabilitation therapy
In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(\>2cm),then drink "Qilisheng"Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Device: Cancer ablation · Drug: Life information rehabilitation therapy
In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Also known as: Cryoblation or irreversible electroporation
Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Also known as: "Qilisheng" Immunoregulatory Oral Solution
Relief degree of tumors
It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）
Time frame: 3 months
Progress free survival（PFS）
The duration between treament and cancer recurrence
Time frame: 1 year
Overall survival
The duration between treament and patient pass way
Time frame: 3 years
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Qilisheng Immunoregulatory Oral Solution
Fuda Cancer Hospital, Guangzhou →